key: cord-0061657-f7g2jl25
authors: nan
title: The 4th European pharmacovigilance congress: speaker abstracts
date: 2021-03-24
journal: Ther Adv Drug Saf
DOI: 10.1177/2042098620987191
sha: 6f5a083cdad145809af900ef0d44f912742a8f4c
doc_id: 61657
cord_uid: f7g2jl25

nan

Introduction 2020 has deeply marked our lives. The COVID-19 global pandemic evolved quickly and brought remarkable uncertainty to long-term forecasts. We have tried to do our best to tackle this unprecedented crisis, adapting to new and troubling challenges at speed. Globally, we have witnessed a race to identify appropriate drugs for the treatment of COVID-19 disease as well as to lavish and desperate efforts to find an effective and safe vaccine. The European Medicine Agency (EMA) has been dealing with a large number of scientific advice procedures for potential medicines to treat COVID-19 and has been in contact with more than 150 developers of potential COVID-19 treatments and vaccines.

During this difficult situation, business continuity has been crucial to ensure that the assessment and monitoring of medicines are being not disrupted, so that patients can continue to have access to medicines during the pandemic. 1 Among the consequences of the COVID-19 crisis, the enrolment and running of clinical trials has been challenging and disrupted. During the pandemic, many hospitals decided to stop the enrolment of patients due to the lack of study protocol compliance; clinics are declining participation and patients are withdrawing their consent for fear of becoming infected during study followup visits. In some instances, sponsors of clinical trials have been discouraged when faced with the possibility of not being able to deliver the drugs to study sites or monitoring the trials as planned. With the aim of reducing interruptions to clinical trials as much as possible, guidance has been issued by health authorities worldwide for the management of studies during the COVID-19 emergency.

Since the beginning of the COVID-19 pandemic, we have witnessed increased occurrences of misinformation, fake and misleading news about promising therapeutic remedies for treatment of coronavirus infection. Disinformation can, in turn, speed up the spread of disease, hinder effective public health responses, as well as creating confusion, fear, and distrust. 2 It is therefore of utmost importance to rely only on trustworthy sources.

During these difficult times, the role of pharmacovigilance is more important than ever. The careful assessment and prompt follow up of any collected safety and efficacy data, combined with the evaluation of the source of information, can produce reliable signal detection for health care practitioners.

The fourth edition of the European Pharmacovigilance Congress, organised by the Pharma Education Centre, was broadcast online on 26-27 November 2020. Updates were provided from international pharmacovigilance organisations such as: the Council for International Organisations of Medical Sciences (CIOMS), the International Society of Pharmacovigilance (ISoP), the Uppsala Monitoring Centre (UMC) and Pharmacovigilance Information and Pharmacovigilance Association (PIPA). Pharmacovigilance experts from competent authorities, marketing authorisation holders, sponsors of clinical trials and patient expert organisations from all over the world attended the event, sharing their experiences and discussing strategies and solutions to address the new emerging needs. 1 

Cultural Organization, https://bangkok.unesco. org/content/press-provides-antidote-fake-newstime-covid-19 (accessed 20 September 2020).

Glyn Belcher PV Consultancy Ltd, London UK Whilst in many signal detection discussions, much emphasis is placed on analyses of data, both quantitative and qualitative, from large company and regulatory agency safety databases, it should not be forgotten that these databases are not the only source of signals of new adverse drug reactions (ADR) of marketed medicines. The data that they contain, mostly spontaneous or solicited reports of suspect ADR without data concerning overall patient exposure to medicines, are probably best suited for identification of signals of rare ADRs that have no or low background prevalence in the population being treated. Safety databases in general are poor sources of data for identification of unknown signals of effects of medicines to increase the frequency occurring commonly in the specific treated population or the population as a whole, such as common cancers and cardiovascular events.

The validation of potential signals obtained from safety databases also poses its own problems. After the three referral procedures and more than 10 years of benefit-risk evaluation, in January 2012, the EU Commission issued a final positive decision and confirmed some use restrictions (i.e. second-line treatment, 100 mg bid/15 days max use, indication restricted to acute pain and primary dysmenorrhea, contraindication for use in patients with known hepatic impairment, children below 12 years, breast-feeding women and during the third trimester of pregnancy). 4 The great majority of nimesulide hepatic adverse events presented confounding factors (i.e. concomitant administration of potentially hepatotoxic drugs, alcohol intake, underlying liver conditions) and a lack of correct drug use (e.g. daily dose higher than recommended and prolonged treatment duration). Adherence to approved dose and duration of treatment, reduced concomitant intake of potential hepatotoxic products (e.g. alcohol and other hepatotoxic drugs), identification of individual risk factors and avoidance in patients with underlying liver diseases were all risk minimisation measures that have helped to prevent druginduced liver disease or reduce its impact in recent years. In addition, risk minimisation actions such as drug utilisation studies, education of prescribers on the correct nimesulide use through educational material and 'Direct Healthcare Professional' letters and ad hoc training sessions kept the possible risks under control.

After 35 years of nimesulide use, the drug is confirmed to have an unchanged and positive benefit-risk profile. More recently, many extra-EU countries are becoming more and more demanding in terms of PV compliance by introducing locally the same requirements as in Europe. However, these multiple activities taking place across several countries introduce a challenge within companies on how to manage multiple PSMFs that are part of the same quality system. The first two requirements to be accomplished are the location of the PSMF and the Qualified Person for Pharmacovigilance (QPPV): both shall be located either at the site where the main PV activities of the MAH are performed or at the site where the QPPV operates.

Thus, the company structure shall be redesigned in order to show the position of the QPPV in the organisation but also the position of the local QPPV, with both reporting to both local upper management and global QPPV.

The PSMF may be arranged in a modular way, having the EU format as a core document and the local description as an addendum. Also, appendices with local information should be organised.

Moreover, it is necessary for the QPPV to introduce a number of inter-related capabilities: delegation of activities to locally trained individuals who will have legal responsibility at a local level, while retaining overall responsibility and guaranteeing oversight of all local PV activities.

Delegation is inevitable for practical implementation of the QPPV role at multiple sites around the world. It is indeed unrealistic to expect any one QPPV to have all the necessary skills and expertise to implement a local PSMF while also being the legal contact point for local competent authorities. In practice, delegation means empowering someone else and giving them the freedom to act. However, as the QPPV always remains accountable, standard operating procedures (SOPs) and related documents are important for capturing the details of delegation.

Thus, as there is no definition in legislation or guidance on how to implement a global PSMF that is open to interpretation, a robust quality assurance and control operation is vital, with the QPPV being central to this process.

Pharm.D., Safety Risk Lead, Director, Pfizer-Scientific Board, Milan, Italy

Communicating information on adverse drug reactions to patients and health care professionals, and explaining how to minimise their severity or the risk of their occurrence is an essential aspect of drug safety. The focus is on ensuring that drugs are taken in the correct way, but the emotional impact that adverse reaction information has on patients is frequently overlooked. Studies have shown that patients perceive the adverse reactions included in the labelling as frightening and, as a result, might alter the drug prescribed dose or might stop taking the drug without consulting a physician. [1] [2] [3] The negative expectations caused by adverse drug reaction information can trigger biological responses that cause nocebo effect symptoms, 4 and can prompt patients not to take the drug as prescribed, thus leading to lack of efficacy. Clinical trials have shown that the nocebo effect affects patients taking placebo 5,6 ; once they are aware of the possibility of experiencing adverse reactions, not only is there a greater chance of experiencing them, but the symptoms they experience also mirror those they have read about in the informed consent. In addition, patients with negative expectations regarding their treatment tend to focus more on the ailments of everyday life and to consider them as drug related. 7 The misattribution of symptoms of daily living to a drug, together with the nocebo effect and the adverse events associated with not taking the drug or not taking it as prescribed, can result in increased adverse event reporting. If drug safety professionals in charge of assessing the safety profile of a drug are not aware that some of the received adverse events reports could be due to the paradoxical effects associated with communicating safety information, these adverse events can be attributed erroneously to the drug and included in the labelling, especially if they originate from sources Abstracts journals.sagepub.com/home/taw 5 other than clinical trials (where adverse events occurring in the investigational medicinal product arm are compared with those associated with a comparator). In fact, it has been found that adverse events occurring less frequently with the active ingredient as compared with placebo are included in the drug labelling (probably because these adverse events originated from post-marketing sources that were considered to be more convincing than clinical trial data, or clinical trial data were not considered). 8 Including in the label adverse events not related to the drug is not trivial since patients have been shown to be unwilling to take drugs even if they are told the medicinal product causes only very few adverse reactions that do not interfere with daily activities. 9 Therefore, the number of adverse reactions included in the label is proportional to the number of patients not willing to take the drug.

It is important not only to avoid including in the label adverse reactions that are caused by the paradoxical effects of communicating them, but also to present adverse reactions in a way that minimises the possibility that patients overestimate the chance of experiencing them, since this is associated with a higher probability that patients will not take the prescribed drug. Studies have shown that lay people tend to overestimate the possibility of experiencing adverse reactions especially when their frequency is presented in non-numeric format (e.g. common, uncommon), 10 and when they are symptoms experienced commonly by patients in everyday life, 11 such as headache or abdominal pain. It is therefore suggested that, for adverse reactions originating from clinical trials, the label reports in numeric format the frequency with which they occur side by side with that of the comparator; the absolute excess frequency with which the adverse reactions occur in association with the drug (as compared with background frequency) should also be reported and the ratio of patients who will not experience the adverse reaction should be specified. Adverse reactions for which causality with the drug has been ascertained should be reported separately from those whose causality is still suspected but not completely ascertained, and, whenever the adverse reaction originates from post-marketing surveillance, in the absolute of its background frequency, the label should state that its frequency is unknown and no estimates should be provided. The Pharmaceutical Information and Pharmacovigilance Association (PIPA) is a membership association for professionals working within the fields of medical information, pharmacovigilance (PV), and related functions in the pharmaceutical industry. PIPA facilitates professional networking to share best practice and raise standards and provides training, tools, and resources to support the PIPA members. This update concentrates on information relevant to PV professionals.

In light of the continuing pandemic, PIPA's 2020 conference was held as a virtual event. It was attended by over 100 delegates, speakers, and exhibitors. Sessions included an update by the MHRA on the Web-RADR 2 project and a presentation by the Association of the British Pharmaceutical Industry (ABPI) on initiatives to improve patient safety. There was also a session on remote auditing (a subject that is particularly relevant this year) and a number of PV-specific workshops. PIPA's face-to-face training courses also had to move to a virtual platform this year, which had its challenges, but, on the positive side, allowed flexibility and removed travel costs.

PIPELINE, the PIPA journal, is usually provided in both hard copy and digital format, but will now be published in digital format only while the pandemic continues. Subjects covered by articles in the latest edition included data integrity and computer system validation, inspection preparation, and virtual audits.

PIPA also offers regular free webinars covering topical subjects including Safety Data Exchange Agreements, Risk Minimisation Measures, Data Protection, Early Access to Medicines Scheme (EAMS), Regulatory guidance in response to COVID-19, reconciliation, and Business Continuity Plans.

One topic that is of particular importance this year is what the end of the Brexit transition period will mean. There have been a few PIPELINE articles and discussions in PIPA webinars as we try to understand the changing guidance and what actions need to be taken to ensure we are prepared. PIPA has also launched a Qualified Person for Pharmacovigilance (QPPV) working group to act as a voice for the role in the UK. As part of the initiative, in April PIPA sent a letter to the Medicines and Healthcare products Regulatory Agency (MHRA) to request a consultation on the future of the UK role post Brexit. Following the MHRA guidance (published in September) that the QPPV for UK authorised products can be based in the EU or the UK (with a National contact person for PV in the UK if the QPPV is based in the EU), the PIPA QPPV working group has been extended to cover EU QPPVs as well as the UK role. The MHRA has already engaged actively with PIPA on this subject, so this will allow PIPA members to gain feedback and insight above and beyond the guidance currently available.

So 2020 has been another busy year for PIPA and I'm proud to be part of it. Despite significant advances in pre-marketing signal detection and safety monitoring, their specific application in older populations remains limited. Whilst older adults represent by far the largest consumer group of medicines worldwide, they are largely excluded from participating in pre-marketing studies. The relatively high prevalence of frailty, co-morbidities, and polypharmacy in the typical older patient managed in clinical practice inevitably clashes with the stringent inclusion and exclusion criteria of clinical trials. Consequently, a significant number of marketed drugs are prescribed off-label in this group. Translating efficacy and safety data obtained in younger cohorts to older adults is also problematic given the high interindividual variability in organ function, homeostatic capacity, and pattern of comorbidities in the latter group. Furthermore, significant pharmacokinetic alterations have been reported in old age, and there is emerging evidence that frailty per se may Abstracts journals.sagepub.com/home/taw 7 also affect the pharmacokinetics of several drugs. Additional issues with assessing drug safety in old age include the non-specific clinical presentation of adverse drug reactions and the increasing evidence that some established drug classes, particularly drugs with anticholinergic properties and sedatives, increase the risk of functional decline and loss of independence over prolonged periods of time. Possible strategies to better predict and identify pre-and post-marketing safety issues in older subjects include (1) facilitating the participation, even as a sub-group for exploratory analysis, of frail older subjects with comorbidities and polypharmacy in pharmacokinetic and pharmacodynamic studies by relaxing some inclusion and exclusion criteria; (2) investigating the specific effects of frailty, and of similar phenotypes associated with advancing age such as sarcopenia, on the pharmacokinetics of new and commonly prescribed drugs; and (3) capturing conventional and non-conventional, for example, functional decline and loss of independence, adverse drug reactions in the community and specific settings, for example, nursing homes and residential care facilities, over prolonged periods of time. The engagement of relevant professional groups and patient associations in different countries is likely to facilitate these steps. This will allow a more robust translation of the knowledge deriving from the pre-marketing safety evaluation in studies of 'real life' older adults into their routine clinical management.

Advisory Board, International Society of Pharmacovigilance Even after 30 years of experience with risk minimisation (RM) of Pharmaceuticals, pharmacovigilance professionals are still challenged by many weaknesses in RM real-life implementation. Ever since the first large-scale risk minimisation programs with a modern type of elements at the end of 20th century, there has been a need for an evidence-based toolbox that would be available to the pharmaceutical industry and regulatory agencies, facilitating the design of effective RM, reducing harm, and improving benefits. Many attempts have been made to contribute to the development of this toolbox, including the CIOMS IX report, multiple United States Food and Drug Administration (FDA) reports and guidelines, RIMES statement, reviews of EU GVP Modules, as well as many declarations and suggestions from various associations.

The presentation provided an overview of the major published contributions to this discussion, but also provided practical experience with a couple of programs the author was involved in. Attendees learned about combinations of RM tools that may work for various situations, regions, cultural and legal conditions, taking into account a proper burden analysis, local implementation plans, and various approaches to evaluation of RM effectiveness.

In conclusion, Dr Petracek shared a practical risk minimisation development and evaluation framework that uses tested tools from patient safety approaches, demonstrated on a couple of real-life examples that pharmacovigilance practitioners might find useful when faced with the risk minimisation tasks. ISoP has been very successful in increasing membership and growing educational offerings in recent years. The COVID situation has had a major impact on the face-to-face training program and conferences. However, ISoP was able to move many of those meetings to the online world and is finding new and innovative ways to support and serve its members and its mission.

ISoP has a growing family of Chapters -geographically organised groups of ISoP members. The Chapters are supported by ISoP leadership in organising local interesting activities, educational events, and more. The scientific work of ISoP members is supported by Special Interest Groups (SIGs), where members share their interest in a particular pharmacovigilance topic and help progress the relevant discussion through publications and presentations. There is no shortage of ideas and many of them are being developed and implemented at ever-increasing speed.

The new communication strategy using social media, as well as organisation of free educational events (e.g. World Patient Safety Day, available on YouTube) has brought major attention to ISoP, showing that ISoP is on the right track to improving its services to members and to pharmacovigilance in general in the upcoming months and years. points that concern the safety of subjects in clinical trials. Firstly, the document clarifies that if an administrative procedure is an essential part of the Investigational Medicinal Product, a reaction that is reported due to such a procedure should be considered as an adverse reaction. A difference between severity, which corresponds to the intensity of the adverse reaction, and seriousness, which corresponds to the outcome, is clarified. In addition, the document provides an updated example of the reference safety information Cascading, additional local contents (in compliance with national and regional regulations) need to be implemented, provided that the content of core documents is also present and kept in consideration. Procedures and responsibilities for addition of local content to core documents (according to local requirements) need to be described in regional/local company procedures.

journals.sagepub.com/home/taw Therapeutic Advances in Drug Safety 12

The continuous effort for process harmonisation, which needs to be done in several activities (including Pharmacovigilance), aiming to improve quality, compliance and cost-effectiveness and to rationalise and simplify processes, may quite often conflict with fulfilment of local requirements.

In this scenario, it is essential to fulfil local specific responsibilities and liability (personal and corporate), but also avoid fragmentation and maintain oversight and effectiveness. This can be obtained by mean of appropriate local and global procedures and a responsibilities matrix. Likewise, a robust coordination process needs to be in place and reflected in the company organisation. A round table focusing on Local and Global Pharmacovigilance (PV) regulations. The topics of PV regulation moving from international to national level and the conflicts between different national PV legislations will be discussed. National requirements for Patient Support Programmes and compliance with PSMF local requirements will also be addressed as well as other eventual questions from the participants.

President Drug and Device Vigilance Consulting LLC, ArisGlobal Advisory Board

For the automation of pharmacovigilance activities, two main applications can be delineated:

• Transactional activities, including ICSR processing, from case intake to distribution • Cognitive activities, ranging from ICSR adjudication, signal detection, issue assessment and ad hoc communications Database workflow systems are used to support transactional activities and introduce automation via robotic process automation (RPA). With the more recent development of AI-associated cognitive computing technologies such as machine learning (ML), deep learning, and reasoning, application support of primarily cognitive functions becomes possible.

There are three main approaches to ML implementation:

• A static approach freezes the ML model after the training run, then uses traditional validation methods similar to the methods used for rule-based programming • A dynamic approach keeps the model in continuous training mode. New data entry simultaneously updates the algorithm. Unfortunately, there are not yet any established regulatory guidelines on validation of a system that by design evolves its specs over time • A hybrid approach freezes the model for periods of time, while simultaneously evaluating all incoming data for the potential effect on the model. If the accumulating data indicate an improvement over the existing model, a mini training-cycle is initiated. The evaluation of the incoming data for model improvement becomes part of the validation package journals.sagepub.com/home/taw 11

To enable ML, a ML model, a training dataset and a validation data set are needed. The training data are used to train the ML model. Text attributes are identified and contextualised through model specific relational attributions of text strings. Model performance is subsequently tested with a separate validation dataset. If test performance is satisfactory, the model is added to a repository. Model specificity and performance are subsequently used to select the production models. When a case narrative is fed into the production tool, it is dissected into relational attributes, assessed for relevance to the desired attributes, and the attributes best compatible with the production specification are provided as output with a confidence score to indicate the degree of certainty of the extraction. A threshold can be set for this confidence score to determine when human verification of the extraction is needed.

ML algorithms learn better with good and precise training material. Better data quality means that fewer training data are needed for the ML algorithm to identify underlying patterns.

Typical methods to generate good training data include

• Scrubbing training data from ambiguous and incomplete data • Annotating training data by adding metadata to the dataset in the form of tags • When training data are limited in quantity or rich in non-essential data elements, adding annotations is essential to ensure appropriate ML model performance. Examples include • Signal detection and evaluation • PV agreements • Aggregate reports • Literature reports ICSRs are the most ubiquitous pharmacovigilance data and usually have a lot fewer unrelated data elements per record. The original case reports have been annotated through the extraction of the needed data elements, which are captured in the associated database record. This can be described as a 'surrogate annotation': while the appropriate text elements have been identified, the context of the original text location is missing. Schmider et al. have demonstrated the viability of using ICSR data directly from the pharmacovigilance database for the training of ML algorithms. 1 A larger training dataset is needed but ICSR data are generally available in large quantities.

In the foreseeable future, the ICSR workflow will be automated end-to-end. Signal detection and aggregate report authoring will be enhanced through automated decision facilitation. Human activities will evolve to an oversight role. It will include the adjudication of machine-identified data attributes associated with confidence scores that fall below a defined threshold. The number of cases processed of signals adjudicated per person will increase significantly over time as the machine learning algorithms become increasingly adjusted and trained. User interface and user experience will shift to the facilitation of the interaction between human intelligence and artificial intelligence: the HI-AI interface.

Moderators: Signal detection is the core of pharmacovigilance. It relies on a mechanism by which safety departments process all the information received Therapeutic Advances in Drug Safety 12

to identify new adverse reactions, or changes in the characteristics of known risks. By delivering essential information to assess the benefit-risk balance of medicinal products, signal detection dictates the ultimate goal of pharmacovigilance.

There are different methods and strategies to conduct an efficient signal detection. For the sake of simplicity, these methods can be grouped in two main categories: (a) quantitative, and (b) qualitative methods. Although a combination of different methods is recommended, generally speaking, quantitative methods are applicable to large datasets, when an individual analysis of all case reports is not feasible, and the role of data mining, artificial intelligence and machine learning software find their more useful application. Qualitative methods are adequate for small datasets that allow an analysis of individual cases or a limited group of cases, with the purpose of identifying elements that raise the suspicion of a new causal association from the clinical description, from the sequence of occurrences or from temporal clusters of events.

Irrespective of which method is used, the quality of data is essential. The current requirements (particularly, GVP module I) emphasise the quality of pharmacovigilance data and explicitly require that holders of marketing authorisations maintain an ADR database, which is not a chaotic repository of confused and unintelligible safety information.

Obviously, to allow identification of a previously unknown ADR, a system to collect and process not only ADRs but also AEs unrelated to the product is compulsory. However, the system must be sufficiently organised to determine causal relationship, case validity, and to allow further analysis to identify unanticipated causal associations. To accomplish this task, efforts should be put to improve informativeness and completeness of each case, and implement coherent, reliable and reproducible causality assessments.

In this light, the presentation of Daniele Sartori, from the Uppsala Monitoring Centre (Signal detection and dissemination to members of the WHO Programme for International Drug Monitoring) discussed important considerations and the captivating suggestion to prioritise those drug-event combinations that have a high proportion of 'informative' reports. This approach can improve the efficiency of signal identification, although it should not be intended as a recommendation to disregard other not fully documented drug event pairs.

Another important observation relating to quality and completeness of the information collected in clinical trials emerged from the interesting talk delivered by Arduino Mangoni, from Flinders University, Australia (Translating pre-marketing adverse drug reactions and signal evaluation to the routine management of the older patient: challenges and opportunities). He stressed the necessity to pay attention to the older population and develop a sound safety knowledge from the developmental phase, and not to postpone it to post-marketing pharmacovigilance. In fact, older patients are the largest population exposed to drugs, but the least studied during clinical trials.

There is an under-representation of older adults, particularly those with multimorbidity and polypharmacy, in clinical trials compared with actual conditions of medicine use in real-world practice. Therefore, it is generally unknown whether the benefits and harms of drugs established through pre-marketing clinical trials are translatable to the real-word population of older adults. Broadening inclusion criteria in pre-marketing trials would enhance the generalisability of the safety findings. Conversely, both Regulators and Sponsors of clinical trials are reluctant to include older patients in their studies due to multiple factors: for instance, older people frequently have concomitant conditions like visual and hearing impairment, impaired coordination, difficulty swallowing, cognitive decline that could lead to a poor adherence and compliance to treatment. A compromise between the necessity to have a homogenous population to test medications and the need that it be representative of people exposed in the real world practice should be considered.

The quality and composition of safety data has changed throughout the years, as Glyn Belcher, from Consultancy Ltd, beautifully explained in his speech (Post-Marketing signal detection -case studies). It questioned the extent to which the expansion of the variety of safety reports, from serious and medically validated to non-serious non-medically validated, has improved or otherwise the accuracy and efficiency of identification of important safety issues. He further elaborated that it is not merely the quantity of reports that generates a signal (thresholds simply based on absolute numbers are inadequate to identify correctly a signal), but the quality of the information The round table discussion took outset in the presentations regarding the evolution of risk management plans, benefit-risk management and decision-making, followed by discussion and response to numerous questions from the audience. A wide range of discussion points were addressed.

Within the field of risk management questions concerned, for example, how to fill the knowledge gaps with regard to potential risks and effectiveness of risk minimisation measures, how to test the effectiveness of risk minimisation measures, how to ensure alignment of risk management plans in different regions and how to include risks in the periodic safety report as compared with the risk management plan. The panel agreed that a detailed pharmacovigilance plan including available tools for testing effectiveness of routine as well as additional risk minimisation measures was mandatory. Register studies is considered a valuable tool, and these may serve several purposes, for example, by generating safety as well as effectiveness data. It is important to predefine goals and desired achievements, for example, level of awareness and change in clinical practice. It is not possible to recommend one particular metric, as every tool or combination of tools has its most optimal metric. It was acknowledged that one significant limitation when evaluating the effectiveness of risk minimisation measures often is the lack of control groups. With regard to alignment of risk management plans across the regions, the panel agreed that development of a core-risk management plan is an appropriate way forward, in combination with content which is tailored according to requests from national regulatory authorities. The different aims of including risks in the risk management plan and in the PSUR was explained. In the risk management plan, risks should only be included in the list of safety concerns if they are subject to additional risk minimisation activities, whereas in the PSURs risks are included to provide a complete risk profile for a product, which is necessary to perform an integrated benefit-risk evaluation.

Within the field of pharmacoepidemiology and benefit-risk assessment questions concerned, for example, whether the method of benefit-risk assessment can be applied to drugs with a wellknown safety profile like generics, how to evaluate a risk, and the required extent of studies on measuring effectiveness with regard to territory. The panel agreed that benefit-risk analysis can be applied in principle to all drugs, provided data of efficacy and safety are available. Besides it was emphasised that in order to evaluate the journals.sagepub.com/home/taw Therapeutic Advances in Drug Safety 12 risk of a particular drug it is necessary to structure the data and to prioritise the different risk, for example, what is the worst possible outcome? It was emphasised that regarding studies aiming at measuring effectiveness of risk minimisation measures it will normally be accepted by the regulatory authorities to perform the studies in a number of representative member states. It was not considered feasible to launch studies in the entire EU. However it was also underlined that health care is organised differently across the EU, and therefore it is of paramount importance that data are generated from several areas.

Moderator: The way clinical trials are conducted in the European Union (EU) will undergo a major change when the Clinical Trial Regulation (CTR) (Regulation (EU) No 536/2014) comes into application, which is planned for December 2021. 1 The Regulation has been adopted by the Council of the European Union and the European Parliament in 2014, and will become law in all EU Member States depending on when the supporting IT infrastructure (EU portal and database) will be fully functional. The Regulation will replace the 2001 EU Clinical Trials Directive that is currently governing clinical trials activities in EU. 2 The EU Clinical Trials Regulation aims to create a more favourable environment for research in Europe, as well as maintain the highest level of standards for patient safety, and increased transparency of clinical trial information. The round 

Geneva: e Council for International Organizations of Medical Sciences, 1998. 2. DIRECTIVE 2010/84/EU of the European Parliament

Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing